| Name | Title | Contact Details |
|---|---|---|
Bashir Ahmed |
Senior Director, R&D IT - Clinical | Profile |
John Krukiel |
Division Vice President US Product Strategy | Profile |
Marwan Sawaked |
Senior Director, R&D GMP QA | Profile |
Vince Fasciocco |
Head of R&D Finance | Profile |
Kratos Analytical is a Spring Valley, NY-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Sigilon Therapeutics’ mission is to create immune-protected, engineered human cells that restore normal physiology in a wide range of diseases without generating fibrosis or immune rejection, liberating patients from challenges associated with serious chronic diseases. We're based in Cambridge, Mass.
New discoveries are revealing the fundamental role of autophagy and lysosomal flux in maintaining cellular health. Furthermore, it is now appreciated that inadequate or aberrant autophagy contributes to a wide range of diseases. We are focused on boosting autophagy – pioneering novel therapeutic strategies to address unmet medical needs. We are creating a new target set for drug discovery and development, and advancing innovative paradigms to treat a broad set of illnesses that are either neglected or inadequately addressed today. Our growing team is driven to transform fundamental discoveries on autophagy into promising therapeutic medicines.
Q32 Bio is a biotechnology company developing therapeutics targeting powerful regulators of the innate and adaptive immune systems, with the goal of re-balancing the immune system in severe autoimmune and inflammatory diseases. Focused on the IL-7 pathway and complement system, Q32 Bio is addressing dysregulation to help patients take back control of their lives in diseases with few to no treatment options, or those diseases where current therapeutics provide inadequate relief.
Nitrome Biosciences has discovered and identified a new class of enzymes.